Dra. Elena Sevillano Fernández M.D. PhD Unidad de Tumores Urológicos, Ginecológicos y piel
HM Hospitales
12.00-12.10h Introducción
EARLY STAGE
12.10-12.30h Non Muscle Invasive
•BGC unresponsiveness
and alternatives
to radical cystectomy?
•Best options
for
patients
after
BCG
12.30-13.30h Muscle Invasive Bladder Cancer
•Neoadjuvant immune
checkpoint
inhibitors
vs neoadjuvant
cisplatin-based
chemotherapy
for
MIBC?
•Bladder sparing
options
vs trimodality
therapy
or
radical cystectomy
•Adjuvant treatment
options
in high
risk
patients
of bladder
cancer
and upper
tract
urothelial
cancer
•New combinations
options
and biomarkers
of response
•Does variant
histologies
change
your
recommendations?
13.30h-14.30h Advanced Disease
•First line current strategies.
Are we evolving towards a platinum-free
future in urothelial cancer?
•Second line therapy: Choosing wisely
•Molecularly guided therapies for
metastatic urothelial cancer
•How FGFR status impacts treatment
decisions and sequencing consideration?
•Antibody-Drug Conjugates: new
winning horse?
•Where are we with treating HER2
genomic alterations?
•Novel biomarkers associated with
treatment outcomes
•What is the role of artificial
intelligence in screening and diagnostic of bladder cancer?
•What is new and on the horizon?